Abstract
As members of the picornavirus family, human rhinoviruses (HRVs) are the major cause of the common cold in humans. In recent years, considerable efforts have been made in the development of anti-HRV compounds targeting rhinovirus enzymes including the viral proteases essential for viral replication. This article summarises the most recent approaches in designing novel HRV 3C protease inhibitors for the treatment of rhinovirus infections.